For BC, the significant association of heterozygous germline LoF variants in BARD1 with early-onset BC (AAD < 50 years) suggests that intensified BC surveillance programs should be offered to women carrying pathogenic variants in BARD1. Here, BARD1 is linked to breast cancer.